|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM210310383 |
| 003 |
DE-627 |
| 005 |
20250213020755.0 |
| 007 |
tu |
| 008 |
231224s2011 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed25n0701.xml
|
| 035 |
|
|
|a (DE-627)NLM210310383
|
| 035 |
|
|
|a (NLM)21795830
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Takada, Tsuyoshi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer
|b a single center experience
|
| 264 |
|
1 |
|c 2011
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 15.09.2011
|
| 500 |
|
|
|a Date Revised 20.11.2014
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Alternative Antiandrogen Therapy with Flutamide in Patients with Castration-Resistant Prostate Cancer : A Single Center Experience We analyzed the clinical effects of flutamide (FLT) as a second-line agent for maximum androgen blockade (MAB) in patients with castration-resistant prostate cancer who received bicalutamide (BCL) as the first-line MAB agent. This study included 44 cases with progressive prostate cancer who had relapsed after first-line MAB, with BCL at 80 mg/day. After checking for antiandrogen withdrawal syndrome (AWS), they were given FLT at 375 mg/day as second-line MAB. A partial response (prostate-specific antigen [PSA] decline ≧50%) and no change (PSA decline of 0-50% or increase ＜25%) by second-line MAB with FLT were achieved in 34.1% (15/44) and 25.0% (11/44), respectively. The median duration of PSA response was 8.2＋/-4.5 months. In multivariate analysis, Gleason score (≦7 vs ≧8), the first-line response (CR vs PR＋NC), and the second-line response (PR＋NC vs PD) were significantly predictive of cause-specific survival from first-line hormonal therapy relapse to cancer death. Our results confirm previous findings that alternative antiandrogen therapy is effective as a second-line hormonal therapy
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Androgen Antagonists
|2 NLM
|
| 650 |
|
7 |
|a Anilides
|2 NLM
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Nitriles
|2 NLM
|
| 650 |
|
7 |
|a Tosyl Compounds
|2 NLM
|
| 650 |
|
7 |
|a Flutamide
|2 NLM
|
| 650 |
|
7 |
|a 76W6J0943E
|2 NLM
|
| 650 |
|
7 |
|a bicalutamide
|2 NLM
|
| 650 |
|
7 |
|a A0Z3NAU9DP
|2 NLM
|
| 650 |
|
7 |
|a Prostate-Specific Antigen
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.21.77
|2 NLM
|
| 700 |
1 |
|
|a Ishizuya, You
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Okada, Takayuki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ueda, Tomohiro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Inoue, Hitoshi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hara, Tsuneo
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 57(2011), 6 vom: 31. Juni, Seite 291-5
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:57
|g year:2011
|g number:6
|g day:31
|g month:06
|g pages:291-5
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 57
|j 2011
|e 6
|b 31
|c 06
|h 291-5
|